• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: August 12, 2025

Key Takeaways

  • Moderate psoriasis treatment is shifting towards patient-centered care and innovative therapies to improve quality of life.
  • Low BSA psoriasis can still result in significant disease burden, challenging traditional treatment criteria.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

It’s Time to Treat Moderate Psoriasis Seriously

Explore the evolving landscape of moderate psoriasis treatment, emphasizing patient-centered care and innovative therapies for improved quality of life.

Low BSA Psoriasis Can Carry High Disease Burden

New insights reveal that those with low BSA involvement often face significant disease burdens, challenging traditional treatment criteria.

Guselkumab Improves QoL in Plaque Psoriasis Patients, According to Long-Term G-EPOSS Study Results

New 76-week data reveals guselkumab's significant benefits for plaque psoriasis, enhancing clinical outcomes, improving quality of life, and reducing stigmatization.

HS Summit Spotlights Gaps in Diagnosis and Care

Steven Daveluy, MD, highlighted lack of awareness and early misdiagnosis as major barriers to effective HS care.

Understanding the Topical Treatment Path for Pediatric Atopic Dermatitis

Tina Bhutani, MD, MAS, highlights emerging topical treatments for pediatric atopic dermatitis, emphasizing improved adherence in younger children, the potential impact of ruxolitinib FDA approval for ages 2 and up, and the promise of ongoing trials in infants under 2 years.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.